Cargando…

The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial

The objective of the present study was to assess the safety and efficacy of a therapeutic vaccine containing both HBsAg and HBcAg (NASVAC) in patients with chronic hepatitis B (CHB) three years after the end of treatment (EOT) as a follow-up of a phase III clinical trial. NASVAC was administered ten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akbar, Sheikh Mohammad Fazle, Al Mahtab, Mamun, Aguilar, Julio Cesar, Yoshida, Osamu, Khan, Sakirul, Penton, Eduardo, Gerardo, Guillen Nieto, Hiasa, Yoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778341/ https://www.ncbi.nlm.nih.gov/pubmed/35062707 http://dx.doi.org/10.3390/vaccines10010045

Ejemplares similares

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment
por: Al Mahtab, Mamun, et al.
Publicado: (2023)

Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)
por: Al Mahtab, Mamun, et al.
Publicado: (2018)

Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon
por: Al-Mahtab, Mamun, et al.
Publicado: (2023)

Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Role of Pegylated Interferon in Patients with Chronic Liver Diseases in the Context of SARS-CoV-2 Infection
por: Akbar, Sheikh MF, et al.
Publicado: (2021)

Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Immune therapies against chronic hepatitis B
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Nature of Host Immunity during Hepatitis B Virus Infection and designing Immune Therapy
por: MF Akbar, Sheikh, et al.
Publicado: (2018)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

Unprecedented rise of monkeypox in Europe and America: Are Asian countries ready for a new outbreak during the ongoing COVID-19 pandemic?
por: Khan, Sakirul, et al.
Publicado: (2022)

Nobel Prize for the Discovery of Hepatitis B and C: A Brief History in Time
por: Al-Mahtab, Mamun, et al.
Publicado: (2020)

Recent downhill course of COVID-19 at Rohingya refugee camps in Bangladesh: Urgent action solicited
por: Khan, Sakirul, et al.
Publicado: (2021)

Dengue Infections during COVID-19 Period: Reflection of Reality or Elusive Data Due to Effect of Pandemic
por: Khan, Sakirul, et al.
Publicado: (2022)

Prevalence of Hepatitis B Virus and Hepatitis C Virus in a Tea Garden of Bangladesh
por: Al Mahtab, Mamun, et al.
Publicado: (2017)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021)

Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers
por: Khan, Md Sakirul Islam, et al.
Publicado: (2020)

Observational study on the response of tenofovir monotherapy versus tenofovir plus telbivudine dual therapy in patients with hepatitis B virus related acute on chronic liver failure
por: Manik, Abul H, et al.
Publicado: (2021)

Co-existence of a pandemic (SARS-CoV-2) and an epidemic (Dengue virus) at some focal points in Southeast Asia: Pathogenic importance, preparedness, and strategy of tackling
por: Khan, Sakirul, et al.
Publicado: (2022)

EDITORIAL
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2019)

Epidemiology of Hepatitis E Virus in an Urban Community in Dhaka City
por: Rahman, Salimur, et al.
Publicado: (2014)

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B
por: Aguilar, Julio Cesar, et al.
Publicado: (2022)

Reply to “Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19”
por: Khan, Md. Saiful Islam, et al.
Publicado: (2021)

Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
por: Khan, Md. Saiful Islam, et al.
Publicado: (2020)

Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19
por: Khan, Md. Saiful Islam, et al.
Publicado: (2020)

Healthcare for non-Covid-19 liver disease patients during the Covid-19 pandemic in Bangladesh: Current trend and future implications
por: Faizul Huq, A. K. M., et al.
Publicado: (2020)

The Journal in the Horizon of Asia and Europe
por: Fazle Akbar, Sheikh Mohammad, et al.
Publicado: (2018)

Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure
por: Hossain, Sharker M. S., et al.
Publicado: (2021)

High Prevalence of Wilson's Diseases with Low Prevalence of Kayser–Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh
por: Choudhury, Nuzhat, et al.
Publicado: (2019)

Genomic analysis of Hepatitis B virus and its association with disease manifestations in Bangladesh
por: Raihan, Ruksana, et al.
Publicado: (2019)

Effect of Granulocyte Colony-stimulating Factor and Erythropoietin on Patients with Acute-on-chronic Liver Failure
por: Haque, Md Nazmul, et al.
Publicado: (2020)

An Outbreak of Acute Hepatitis in a Medical Facility of Bangladesh
por: Al Mahtab, Mamun, et al.
Publicado: (2014)

Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh
por: Islam, Md Azizul, et al.
Publicado: (2020)

A Dynamic Mathematical Modeling Revelation about the Impact of Vaccination on Hepatitis B Virus-induced Infection and Death Rate in Bangladesh
por: Chakraborty, Sajib, et al.
Publicado: (2019)

Hepatic Venous Pressure Gradient Measurement in Bangladeshi Cirrhotic Patients: A Correlation with Child’s Status, Variceal Size, and Bleeding
por: Al Mahtab, Mamun, et al.
Publicado: (2017)

Characterization of Liver Monocytic Myeloid-Derived Suppressor Cells and Their Role in a Murine Model of Non-Alcoholic Fatty Liver Disease
por: Yao, Liying, et al.
Publicado: (2016)

Five-year Follow-up of Chronic Hepatitis B Patients Immunized by Nasal Route with the Therapeutic Vaccine HeberNasvac
por: Fernández, Guillermo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j9l3nbf7dljou9fedppf7kil43